




Ambulatory Sleeve Gastrectomy: A Non-inferior Option for Bariatric Patients

S. Julie-Ann Lloyd, Christiana Peek, Sarah Mahlke, Qianzi Zhang,
Jose Euberto Medez Reyes, Juliet Holder-Haynes, Samer Mattar
Baylor College of Medicine
Houston, TX



XXVII Ifso World Congress




Melbourne 2024

I have the following potential conflict(s) of interest to report:

- Travel support
 - Gore
 - Intuitive

Benefits of Metabolic and Bariatric Surgery (MBS)

- Safe, effective treatment for obesity and related co-morbidities





- Reported mortality rate 0.14% from Bariatric Outcomes Longitudinal Database (BOLD) study
- Factors that influence these results:
 - Standardization of care
 - Multi-disciplinary approach
 - Pre-operative optimization
 - Minimal invasive techniques
 - **Enhanced recovery after surgery (ERAS) protocols**
 - Outcomes review and accreditation

DeMaria EJ et al. Surg Obes Rel Dis 2010;6(4):347-55

Sjöström et al. JAMA 2012;307(1):56-65.

Sleeve Gastrectomy

- Accounts for almost 70% of all bariatric procedures performed in the United States



Methods

- Study Setting:
 - Single, high-volume, MBSAQIP-accredited institution with fellowship-trained surgeons
- Patient Selection:
 - Primary, elective sleeve gastrectomy, January 2020 – May 2023
 - Age \geq 18 years
 - BMI \geq 35 kg/m²
 - Absence of significant cardiac or pulmonary disease
 - Able to ambulate
 - Adequate support at home
 - Stay within one hour of the hospital

Methods

- Exclusion criteria:
 - Uncontrolled diabetes or untreated sleep apnea
 - Cardiac disease without prior revascularization
 - End-stage renal or severe liver disease or listed for transplant
 - Revisional surgery
 - Inadequate follow-up at 30 days post-operatively



Methods



Pre-operative consultation

- Education and expectations



Clinical weight management program



Surgery

- ERAS
- Early case start
- Nutritionist
- Discharge criteria*
- Verify meds at home



Check-in via telephone

- Within 24 hours and on POD3/4
- Return for IVF if needed

❖ Discharge criteria:

- 3-hour min stay in recovery
- Blood glucose controlled, <180
- Able to follow instructions
- Passed water trial and tolerating clear liquid diet

Results



Propensity
matching

Baseline Demographics of Matched Cohort

| Characteristics | Ambulatory Group | Control Group | p value |
|---|-------------------|-------------------|---------|
| Total Number of Patients (n) | 51 | 177 | |
| BMI (Pre-op, kg/m ²) – median [IQR] | 43.4 [40.2, 49.4] | 43.5 [39.8, 48.8] | 0.831 |
| Age at Surgery – median [IQR] | 32.0 [28.5, 42.5] | 35.0 [30.0, 41.0] | 0.311 |
| Sex = Female – n (%) | 49 (96.1) | 165 (93.2) | 0.676 |
| Race – n (%) | | | 0.916 |
| White | 25 (49.0) | 86 (48.6) | |
| Black or African American | 24 (47.1) | 86 (48.6) | |
| unknown | 2 (3.9) | 5 (2.8) | |
| Current Smoker – n (%) | 8 (15.7) | 16 (9.0) | 0.27 |
| Diabetes Mellitus – n (%) | 9 (17.6) | 46 (26.0) | 0.298 |
| Sleep Apnea – n (%) | 19 (37.3) | 60 (33.9) | 0.782 |
| Hypertension – n (%) | 13 (25.5) | 60 (33.9) | 0.335 |
| Hyperlipidemia – n (%) | 12 (23.5) | 38 (21.5) | 0.903 |
| ASA Classification – n (%) | | | 0.872 |
| ASA 2 | 4 (7.8) | 16 (9.0) | |
| ASA 3 | 46 (90.2) | 159 (89.8) | |
| ASA 4 | 1 (2.0) | 2 (1.1) | |

No Significant Differences in Adverse Outcomes

| Variable | Ambulatory Group | Control Group | p value |
|-------------------------------------|---------------------|--------------------|---------|
| Operative time (min) (median [IQR]) | 121.2 [87.6, 140.4] | 75.6 [64.2, 127.8] | <0.001 |
| Composite adverse event (%) | 0 (0.0) | 12 (6.8) | 0.12 |
| Post-operative VTE (%) | 0 (0.0) | 2 (1.1) | 1.0 |
| Post-operative UTI (%) | 0 (0.0) | 2 (1.1) | 1.0 |
| Outpatient IVF infusion visits (%) | 2 (3.9) | 8 (4.5) | 1.0 |
| Emergency room (ER) visits (%) | 7 (13.7) | 22 (12.4) | 0.813 |
| 30-day readmission (%) | 0 (0.0) | 11 (6.2) | 0.129 |
| 30-day reintervention (%) | 0 (0.0) | 6 (3.4) | 0.342 |


Regression Analysis

- ER visits associated with 3 variables:

| Variable | Coefficient (<i>p</i> -value (std error)) |
|-------------------|--|
| Private insurance | 0.0142* (0.43839) |
| History of reflux | 0.0253* (0.56272) |
| Robotic approach | 0.0162* (0.59608) |

- $R^2 = 0.135$
- Sample size, $n = 228$

Equivalent Weight Loss



| | Ambulatory Group | Control Group | <i>p</i> value |
|--------------------------|------------------|---------------|----------------|
| %TWL at 3 mo – mean (SD) | 14.27 (4.20) | 15.13 (4.40) | 0.296 |
| %TWL at 6 mo – mean (SD) | 20.41 (5.85) | 20.51 (6.32) | 0.937 |

Limitations

- Single center, small sample size
- No randomization; selection bias
- Potential confounders:
 - Over-representation of robotic approach among ambulatory cases
 - High proportion of government insurance coverage

Me re-reading my own paper when it's finally online




Conclusions

- Ambulatory sleeve gastrectomy can be safely performed in the bariatric population
- Same-day discharge does not affect early-term weight loss results
- These findings may be translatable to other bariatric procedures



Questions?

S. Julie-Ann Lloyd, MD, PhD, FACS, FASMBS, DABOM
Assistant Professor
Baylor College of Medicine
SJLLOYD@BCM.EDU



XXVII Ifso World Congress



Melbourne 2024